Biofrontera AG announced the appointment of Christoph Dünwald as Chief Commercial Officer. Mr. Dunwald will lead the sales and marketing of the Group as a member of the management board, which he is envisaged to join with effect from November 16, 2015, due to an existing non-compete clause. Mr. Dünwald brings 24 years of comprehensive sales and marketing expertise in the healthcare sector which he gained working for pharmaceutical businesses in Europe, Asia Pacific and the US.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.085 EUR | -5.66% | -44.74% | -51.49% |
May. 15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
Apr. 30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.49% | 11.76M | |
+32.36% | 694B | |
+29.65% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.48% | 239B | |
-3.48% | 209B | |
+10.07% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- B8FK Stock
- News Biofrontera AG
- Biofrontera AG Appoints Christoph Dünwald as Chief Commercial Officer